BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 20800920)

  • 1. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study.
    Piroth L; Pol S; Lacombe K; Miailhes P; Rami A; Rey D; Loustau-Ratti V; Morlat P; Goderel I; Sene D; Rosenthal E; Carrat F; Cacoub P;
    J Hepatol; 2010 Dec; 53(6):1006-12. PubMed ID: 20800920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY).
    Piroth L; Sène D; Pol S; Goderel I; Lacombe K; Martha B; Rey D; Loustau-Ratti V; Bergmann JF; Pialoux G; Gervais A; Lascoux-Combe C; Carrat F; Cacoub P
    AIDS; 2007 Jun; 21(10):1323-31. PubMed ID: 17545709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
    J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study.
    Piroth L; Pol S; Miailhes P; Lacombe K; Lopes A; Fillion A; Loustaud-Ratti V; Borsa-Lebas F; Salmon D; Rosenthal E; Carrat F; Cacoub P;
    Liver Int; 2015 Aug; 35(8):1950-8. PubMed ID: 25559645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
    Jain MK; Comanor L; White C; Kipnis P; Elkin C; Leung K; Ocampo A; Attar N; Keiser P; Lee WM
    J Viral Hepat; 2007 Mar; 14(3):176-82. PubMed ID: 17305883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
    Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.
    Maylin S; Boyd A; Lavocat F; Gozlan J; Lascoux-Combe C; Miailhes P; Lassel L; Delaugerre C; Girard PM; Zoulim F; Lacombe K
    AIDS; 2012 May; 26(8):939-49. PubMed ID: 22333748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
    Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
    Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
    AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
    Alvarez-Uria G; Ratcliffe L; Vilar J
    HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy.
    Laurent C; Bourgeois A; Mpoudi-Ngolé E; Kouanfack C; Ciaffi L; Nkoué N; Mougnutou R; Calmy A; Koulla-Shiro S; Ducos J; Delaporte E
    HIV Med; 2010 Jan; 11(1):85-9. PubMed ID: 19659944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B.
    Plaza Z; Aguilera A; Mena A; Vispo E; Sierra-Enguita R; Tomé S; Pedreira J; Rodriguez C; Barreiro P; del Romero J; Soriano V; Poveda E
    AIDS; 2013 Sep; 27(14):2219-24. PubMed ID: 23669158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
    Manesis EK; Papatheodoridis GV; Tiniakos DG; Hadziyannis ES; Agelopoulou OP; Syminelaki T; Papaioannou C; Nastos T; Karayiannis P
    J Hepatol; 2011 Jul; 55(1):61-8. PubMed ID: 21145875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of CD4+ T-cell counts and plasma HIV-1 RNA levels with serological HBeAg/anti-HBe patterns obtained in West-African HBV-HIV-1-co-infected children.
    Rouet F; Chaix ML; Kpozehouen A; Inwoley A; Anaky MF; Fassinou P; Rouzioux C; Blanche S; Msellati P
    J Trop Pediatr; 2009 Dec; 55(6):409-12. PubMed ID: 19447821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
    Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ;
    J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in north India.
    Gupta S; Singh S
    BMC Infect Dis; 2010 Mar; 10():53. PubMed ID: 20205948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
    Amini-Bavil-Olyaee S; Sheldon J; Lutz T; Trautwein C; Tacke F
    AIDS; 2009 Jan; 23(2):268-72. PubMed ID: 19098499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
    Sheng WH; Hung CC; Chang SY; Liu CJ; Chen MY; Hsieh SM; Kao JH; Chen PJ; Chang SC
    Clin Infect Dis; 2012 Feb; 54(4):548-55. PubMed ID: 22156858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
    Pan CQ; Hu KQ; Yu AS; Chen W; Bunchorntavakul C; Reddy KR
    J Viral Hepat; 2012 Mar; 19(3):213-9. PubMed ID: 22329376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.